4-Year follow-up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero

      We have previously found 17P treatment to prevent recurrent preterm birth and infant morbidity when given to women with prior spontaneous preterm births. The purpose of this long-term follow-up evaluation was to determine if there are evident adverse effects of 17P after in-utero exposure.
      To read this article in full you will need to make a payment